% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Merz:127948,
      author       = {M. Merz$^*$ and T. Hielscher$^*$ and B. Wagner$^*$ and S.
                      Sauer and S. Shah and M. S. Raab$^*$ and A. Jauch and K.
                      Neben and D. Hose and G. Egerer and M. A. Weber and S.
                      Delorme$^*$ and H. Goldschmidt and J. Hillengass$^*$},
      title        = {{P}redictive value of longitudinal whole-body magnetic
                      resonance imaging in patients with smoldering multiple
                      myeloma.},
      journal      = {Leukemia},
      volume       = {28},
      number       = {9},
      issn         = {1476-5551},
      address      = {Basingstoke},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2017-03970},
      pages        = {1902 - 1908},
      year         = {2014},
      abstract     = {Previous studies demonstrated the relevance of focal
                      lesions (FL) in whole-body magnetic resonance imaging
                      (wb-MRI) at the initial workup of patients with smoldering
                      multiple myeloma (SMM). The aim of this study was to assess
                      the effects of longitudinal wb-MRIs on progression into
                      multiple myeloma (MM). Sixty-three patients with SMM were
                      analyzed who received at least two wb-MRIs for follow-up
                      before progression into MM. Radiological progressive disease
                      (MRI-PD) was defined as detection of new FL or increase in
                      diameter of existing FL and a novel or progressive diffuse
                      infiltration. Radiological stable disease (MRI-SD) was
                      defined by no change compared with the prior MRI. Patients
                      were followed-up every 3-6 months, including a serological
                      and clinical evaluation. One Hundred and eighty-two wb-MRIs
                      were analyzed. MRI-PD occurred in 31 patients $(49\%),$ and
                      25 $(40\%)$ patients developed MM. MRI-PD was highly
                      significantly associated with progression into MM,
                      regardless of findings at the initial MRI. In multivariate
                      analysis, MRI-PD remained a risk factor, independent of
                      relevant baseline parameters like serum monoclonal protein
                      or $⩾95\%$ aberrant plasma cells in the bone marrow.
                      Patients with MRI-SD had no higher risk of progression, even
                      when FL were present at the initial MRI. Therefore, MRI is
                      suitable for the follow-up of patients with SMM.},
      cin          = {E010 / C060 / E013 / G330},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)E013-20160331 / I:(DE-He78)G330-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24535407},
      doi          = {10.1038/leu.2014.75},
      url          = {https://inrepo02.dkfz.de/record/127948},
}